Royalty Pharma
RPRX
123 hedge funds and large institutions have $8.96B invested in Royalty Pharma in 2020 Q2 according to their latest regulatory filings, with 123 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
70% more call options, than puts
Call options by funds: $2.63M | Put options by funds: $1.54M
41.04% more ownership
Funds ownership: 0% → 41.04% (+41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.28B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$810M |
| 3 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
+$727M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$403M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$397M |
Top Sellers
RPRX Hedge Fund Activity: Q2 2020 in Review
123 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2020, worth a combined $8.96B.
Buyers outnumbered sellers: 123 funds opened new RPRX positions and 0 closed out — a net gain of 123 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $2.28B.
- 123 institutional investors held Royalty Pharma (RPRX) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $8.96B of Royalty Pharma stock for Q2 2020.
- 123 funds opened new Royalty Pharma positions in Q2 2020 and 0 closed out, a net change of +123 holders.
- The largest Royalty Pharma buyer in Q2 2020 was Adage Capital Partners, an estimated $2.28B added.
Based on aggregated 13F filings for Q2 2020.